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Introduction: Cardiogenic shock is a sudden complication that occurs in 5 to 10% of 
patients with acute myocardial infarction. According to statistics, mortality and 
morbidity from this event, despite all hospital care, are approximately 70-80%. 
Methods: This study was conducted over three years (2012 to 2014) in 28 cases of 
acute myocardial infarction, which was complicated by cardiovascular shock, before or 
after admission. We compared the outcomes of patients according to the treatment 
strategy, thrombolytic therapy, primary percutaneous coronary intervention (PCI), or 
other medical stabilization. The 30-day follow-up was the first endpoint, and the 3-
month follow up was the second endpoint of the study. 
Results: 28 patients with cardiogenic shock included in this study. The mean (± SD) 
age of the patients was 62.99 ± 13.99 years. The median time to the onset of shock was 
648.75 ± 1393.58 minutes after infarction. Most of the patients who underwent 
coronary angiography had 3-vessel or left main involvement. Two patients missed in 
follow up and five (80%) patients who received thrombolytic therapy passed away. Nine 
(100%) patients in the medical stabilization group and six patients (50%) underwent 
primary PCI group passed away too. The mortality in the primary PCI group was 
significantly lower than the other groups (P = 0.04) 
Conclusion: Although cardiogenic shock is a potential risk of early death, it is 
important that the thrombolytic in these patients doesn't increase survival and the 
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INTRODUCTION
According to studies, five to ten percent of patients with 
acute myocardial infarction (MI) were complicated by 
cardiovascular shock (CS) [1] and despite all numerous 
actions, it is still the cause of death in patients with 
myocardial infarction, who were admitted in the 
hospital resuscitation era [2-4]. 
Most of patients with cardiogenic shock, because of 
doubt on the effectiveness, do not take primary 
revascularization [5]. The in-hospital death ratio due to 
cardiogenic shock is widely high (50-84%) because 
there is no certain treatment to reestablish blood flow in 
the infarct coronary arteries and restore myocardial 
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function [6]. Extensive studies on thrombolytic agents 
treating cardiogenic shock with MI, resulted in 60% 
mortality with the most effective thrombolytic agents. A 
new approach is to use more urgency aggressive 
therapeutic interventions, in cases who have cardiogenic 
shock due to acute Myocardial infarction [7] Some trials 
reported decreased mortality rates among patients who 
have undergo nearly revascularization after cardiogenic 
shock [8, 9]. However brief bias seen [10].At the 
moment, in spite of all current researches on most 
efficient considerations for return left ventricular 
function and flow also reduce infarct size, finding more 
effective approaches to decrease loses ratio, 
complications and improve prognosis is essential. It is 
also important to be studied the prevalence of cardiac 
shock due to the complications of acute myocardial 
infarction, its mortality rate and the possible effect of 
new treatment strategies. 
We performed a 3-years-study (2012-2014) to extend 
the finding of a report on comparison the efficacy of 
thrombolytic therapy, primary PCI and also medical 
therapies, in the management and outcomes of CS, 
among patients with confirmed acute MI (i.e. non ST 
elevation, and ST elevation), who had been admitted to 
an academic hospital of Iran. 
The aim of the present study is to determinate short and 
long term survival with thrombolytic agents in patient 
with MI complicating by CS. 
METHODS 
Data Source 
This study is a retrospective observational study with 
census sampling, comparing three treatment strategies, 
thrombolytic agents, primary PCI and initial medical 
stabilizations in cardiogenic shock in patients with acute 
MI. Patients were enrolled from April 2012 to April 
2014 at the academic Loghman hospital of IRAN, and 
we used information from discharge abstracts derived 
from state-mandated hospital discharge reports. The 
patients were followed up after 3 and 6 months. We 
obtained all patient’s satisfactory for ethical rules. 
Study Population 
We used 28 cases with suspected CS as a 
complicated of MI, that determined at the sustained 
hypotension (systolic blood pressure < 90mmHg 
for ≥ 30min) and reduce cardiac index in the 
presence of normal or elevated pulmonary capillary 
wedge pressure (> 15 mmHg) or right ventricular 
end-diastolic pressure (> 10mmHg). Our data 
sampling was according to the number of 
documented information we have found. 
Outcomes Measured 
We extract demographic data, medications, lab tests, 
ECG, echocardiographic and angiographic data from 
the medical documentation. Hospital mortality and 
30 days and three months of mortality (by phone 
interview) was also recorded. 
Statistical Analysis 
A continuous variable presented as mean ± 
standard deviation and categorical variables are 
presented as number and percentages.  
Independent t-test, chi-square have been used for 
the analysis of continuous and categorical data. All 
the statistical analysis was performed using the 
SPSS 16.0 statistical software. We didn’t enroll 
missing cases in survival measuring. 
 
Table 1. Baseline Demographic and Clinical Characteristics 
Demographics  
Age (years) 62.96±13.99 
Male sex (%) 16(57.1%) 







Prior PCI 1(3.6%) 
Prior CABG 3(10.7%) 
Current smoking 7(25%) 
Previous ASA use 10(35.7) 
Presentation features  
Typical chest pain (%) 21(75%) 
Dyspnea (%) 15(53.5)% 
Vital sign  
Initial heart rate(beat/min) 90.35± 24.60 
Initial respiratory rate (per min) 19.54 6.55 
Initial O2sat (%) 90.50 ± 6.20 
Initial systolic blood pressure (mm 
Hg) 
89.71 ± 23.59 
ECG findings (%)  
STEMI 23(82.1%) 
Non-STEMI 1(3.6%) 
Unstable angina 4(14.3%) 
Ant STEMI 11(39.1%) 
Laboratory results  
Hemoglobin (mg/dl) 12.22 ± 2.08 
Platelets (mg/dl) 214790± 78741.72 
Creatinine (mg/dl) 1.68 ± 0.99 
INR 1.35 ± 0.69 
Highest total CPK (IU/L) 1917.3 ± 2537.0 
Highest CKMB (IU/L) 178.7± 204.71 
Ischemic time(min) 1302.0±1773.1 
Time from onset of MI to shock 
(min) 
648.75±1393.58 
Data in table are presented as No. (%) or Mean ± SD. DM: 
Diabetes mellitus; HTN: Hypertension; DLP: Dyslipidemia; 
CAD: Coronary artery disease; CVA: Cerebrovascular Accident; 
HF: Heart failure; PCI: Percutaneous coronary intervention; 
CABG: Coronary artery bypass graft; STEMI: ST-segment 
elevation myocardial infarction; INR: International 
normalization ratio. 
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RESULTS 
Patients and Clinical Findings 
The total number of population was 28 cases. The mean 
age of the study population was 62.96 ±13.99 years (40 
to 95 years) and 16 patients were male (57.1%). Also, 
23(82.1%) were presented with ST Elevation MI 
(STEMI) and 1(3.6%), non ST elevation MI 
(NSTEMI), and 4(14.3%) presented with UA. 
11(39.1%) were presented by Anterior STEMI, and 
6(21.43%) presented by Inferior MI. The mean time of 
symptom onset until the hospital arrival was 
(1302.0±1773.1) min (Table 1). 
More than half of the patients were 3-vesslel disease or 
left main disease. Angiography did not perform in 
11(39.2%) of the patients. The mean time of onset to 
angiography among 14 cases was (950.43±1396.09) 
min that recorded. 
 
Table 2. Echocardiography and angiography findings 
Echocardiography results  
EF (%) 31.9 ± 14.6 
MR (%)  
 Mild (<2) 58.3% 
 Severe (≥2) 8.3% 
Angiography results (n=17)  
Single vessel disease 0(0%) 
2-vessel disease 8(47.0%) 
3-vessel disease 7(41.1%) 
Left main disease 2(11.7%) 
NO angiography process 11(39.2%) 
Time to angiography (min) 950±1396.09 
Time to death (min) 5500.7±7266.5 
Data in table are presented as No. (%) or Mean ± SD. EF: Ejection 
fraction; MR: Mitral regurgitation 
Treatment 
Drugs that were prescribed in the hospital’s course were 
recorded (Table 3). Among those who treated with 
thrombolytic agents (six cases), one patient referred to 
another hospital, so we didn't mention him in survival 
results. Among five others in thrombolytic group, one 
patient underwent urgency PCI, after an unsuccessful 
thrombolytic (but he passed away), 4(80%) cases from 
thrombolytic group didn’t survive. 
A 13(46.4%) of cases in this study were underwent 
primary PCI, in this group, one patient excluded from 
survival analysis because of missed follow up. In 
addition, in this group seven patients (58.33%) 
underwent intra-aortic balloon pump insertion with 
primary PCI that five of them (71.42%) didn’t make 
it. 
 No one in this study underwent coronary artery bypass 
grafting and six patients who used medical therapies, 
also passed away (Fig 1). 
Generally, we had 18 cases (64.3%) who passed away 
and eight cases (28.6%) who survived. Also two patients 
with unknown documents (refer to other hospitals). 
The mean time of the onset to death was 
(5500±7266.47) min. 
 
Table 3. In hospital medication and interventions (for all patients) 





IIBIIA inhibitors 6(21.4%) 








Primary PCI 13(46.4%) 
Primary PCI+IABP 7(25%) 
Data in table are presented as No. (%) or Mean ± SD. LMWH: Low 
molecular weight heparin; PCI: Percutaneous Coronary Intervention; 
IABP: Intra-aortic balloon pump. 
Survival 
The mean age was 56.75 ± 10.07 years for survival 
group, 66.27± 14.36 years for mortality group. 66.66% 
of the mortality group was male gender. In the survived 
group 6 (75%) patients underwent primary PCI while 6 
(33.33%) patients who didn’t survive underwent 
primary PCI (P = 0.04). 
All of escaped patients were alive for at least 90 days. 
 
 
Figure 1. Flowchart of patients (PCI: Percutaneous coronary intervention; IABP: intra-aortic balloon pump) 
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Table 4. Comparison of the patient with shock according to mortality 
Characteristics Survival (n=8) Mortality (n=18 P value 
Age (year) 56.75±10.07 66.27±14.36 0.10 
Male sex 4 (50%) 12 (66.66%) 0.42 
History of DM 4 (50%) 7 (38.88) 0.59 
History of HTN 2 (25%) 10 (55.55%) 0.15 
History of DLP 0 (0%) 5(27.77%) 0.97 
Prior PCI 0(0%) 1 (5.55%) 0.50 
Prior CABG 0(0%) 3(16.66%) 0.22 
STEMI 7(87%) 14 (77.77%) 0.661 
NSTEMI 0 (0%) 1 (5.55%) 0.65 
Ant STEMI 2 (25%) 7 (38.88%) 0.195 
1VD 0(0%) 0 (0%)  
2VD 1(12.5%) 2(11.11%) 0.31 
3VD 2 (25%) 3(16.66%) 0.92 
LM 0(0%) 1(5.55%) 0.42 
Thrombolytic 1(12.5%) 4(22.22%) 0.562 
Medical therapy 0(0%) 6(33.33%) 0.63 
Primary PCI 6(75%) 6(33.33%) 0.049 
IABP 1(12.5%) 2(11.11%) 0.919 
Primary PCI+IABP 2(25%) 5(27.77%) 0.860 
 
DISCUSSION
The result of this population-based study represents a 
significantly higher in-hospital death ratio in cases with 
acute MI complicated by cardiogenic shock. Necessary 
efforts to reduce the incidence of cardiogenic shock 
should focus on rapid diagnosis of patients who are at 
high risk for this complication and requires 
recommendations to seek immediate care after the 
onset of coronary symptoms. AS already noticed, in this 
study 69% of CS patients were passed away, as other 
studies reported. 
Therefore, appropriate and permanent monitoring, risk 
classification, and deserving intervention should be 
considered [11]. A large number of patients developed 
shock after presenting to the hospital. This is important 
that medical contact should be considered seriously 
before the onset of shock [12]. Significantly typical 
chest pain was a predecessor of cardiac arrest in 66% of 
patients and 56% of the patient had Ant MI [13]. In 
many studies showed that there has been a priority ratio 
in the proportion of men than in women with STEMI 
which ongoing to cardiogenic shock [14]. In this study, 
82.1%of patients presented with STEMI and that shows 
the incidence of cardiogenic shock among STEMI is 
more than NSTEMI. Moreover the majority of cases 
with the development of shock had multi-vessel disease 
(81%) [15], likewise our results. Many studies reported 
that most of mortality group in STEMI were the 
multivessel disease. 
Patients who temporarily survived cardiogenic shock as 
a fatal complication of acute myocardial infarction, have 
good functional status with long-term survival [16]. 
Shock trial reported that long-term survival was 
significantly higher with early revascularization resulted 
in a 13.2% absolute and a 67% relative improvement in 
six years survival [17]. In another study, 30-days survival 
of the patients who underwent revascularization were 
similar or better than group who did not routinely 
receive invasive therapy [18]. In present study 30 and 90 
days survival was 30.7% that means all the patient who 
survived after 30 days discharging from hospital, had 90 
days survival too. 
Generally, thrombolysis shifts the period of myocardial 
rupture, with an increase in early and reduction in late 
myocardial rupture. On the whole, the rate is reduced. 
Rupture generally expected in patient with small infarct 
size and shock [19], however shock ordinarily develops 
in a patient with severe left ventricular damage [16]. In 
GUSTO-1(Global Utilization of Streptokinase & 
Tissue Plasminogen Activator for Occluded Arteries) 
trial, 57%of all patients developed cardiogenic shock 
after thrombolytic therapy, died in the hospital [20]. 
Not many randomized controlled trials have reached the 
conclusion that the use of thrombolytic agents can 
reduce or improve survival after onset of cardiogenic 
shock. This study, found the mortality ratio in the 
Thrombolytic group was 80%. It seems that the use of 
thrombolytic does not increase survival in patients 
whose cardiogenic shock is going to develop. 
Also, The Swiss multicenter trial of angioplasty shock 
(SAMSH) trial announce the decrease mortality rates in 
patients whom underwent invasive interventions 
compare to patients who underwent initial medical 
stabilization [21]. The results showed that the benefit of 
these interventions on an individual's performance and 
long-term survival in patients with the development of 
cardiogenic shock as a result of AMI. As we notice in our 
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study, the mortality ratio in patients who underwent 
primary PCI was 50%, in other meaning. 
A meta-analysis of 23 large randomizes trial have 
reported the primary PCI is preferred to thrombolysis 
for prompt treatment of STEMI. The preference due to 
a high impact on the reopening of the coronary artery 
and restore flow in these vessels and reduce re-
obstruction of the artery and recurrent ischemia. Also, 
improve the remained of left ventricular function and 
ultimately better clinical outcomes [22]. The shock trial 
showed that a strategy of early revascularization grants a 
one-year survival benefits than initial medical 
stabilization with delayed revascularization among 
patient presenting with cardiogenic shock complicating 
by acute MI [23]. Although the shock occurs in a patient 
with severe left ventricular damage, the importance of 
early revascularization is because of interruptions in 
remodeling procedures that appear due to MI, 
Moreover it pause consequences of decreased 
contractility of cardiac myocardial, and myocyte 
necrosis [16]. 
CONCLUSION 
CS is a treatable event with a very acceptable prognosis 
[24]. It is essential to diagnosis and rapid interventions 
for these patients because CS patients are at very high 
risk for early death. Primary PCI is associated with more 
benefits and survival ratios against thrombolytic and 
also medical stabilization. This study shows the 
importance of prompt attention to aggressive early 
procedures even in unstable patients. 
Limitations 
This study is an observational retrospective study with a 
minimal population, so the groups are not matched and 
the result of this study cannot be generalized. Some of 
the data like echocardiography results or angiography 
findings were incomplete. Also, we missed two patients 
to follow. 
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